非小细胞肺癌患者细胞学标本EGFR基因突变检测及其临床病理意义

doi:10.3969/j.issn.1004-616x.2016.01.006

Abstract

Abstract: OBJECTIVE: To investigate the clinical value of cytological specimens in the diagnosis and the individualized treatment of non-small cell lung cancer(NSCLC). METHODS: Cytological specimens were stained with HE and with immunocytochemical method to detect expression of an appropriate set of antibodies (TTF-1 NapsinA,CK7,CEA,CD56,Syn,P63,CK5/6,WT-1,E-cadherin),in tumor cells of unknown origin. The epidermal growth factor receptor(EGFR) gene was detected by the amplification refractory mutation system(ARMS) in NSCLC. RESULTS: In 352 patients,345 cases were found cancer cells on the cytological specimens.According to the clinical history and immunocytochemical staining of the 345 malignant cases,335 were NSCLC cytological samples,and the DNA of 302 NSCLC samples were extracted successfully (satisfaction rate at 90.15%). EGFR mutations were detected in 123 of the 302 specimens (40.73%,123/302) and the frequencies of EGFR mutations in exon18,19,20(T790M),21 were 0.99% (3/302) 19.21%(58/302),0.66%(2/302) and 19.87% (60/302),respectively. Higher frequencies of EGFR mutations were detected in exons 18,19 and 21(98.37%,121/123) than in exon 20(P<0.05). EGFR mutations were more frequently detected in women(54.35%,75/138) than in men (29.27%,48/164)(P<0.05),and in non-smokers (51.49%,104/202) than in smokers 19%(19/100)(P<0.05). Mutations were identified in 44.20%(122/276) cases of adenocarcinoma and 4.34%(1/23) in nonadenocarcinoma. Mutation of EGFR gene in adenocarcinoma was higher than that in non-adenocarcinoma(P<0.05). CONCLUSION: The use of cytological specimens in combination with immuno-cytochemical staining and molecular techniques helps in the diagnosis of advanced cancer and individualized treatment option of NSCLC.

Key words: cytological specimens, immunocytochemical, non-small cell lung cancer, amplification refractory mutation system, EGFR gene mutation detection

CLC Number:

R734.2

WU Juan, DU Yun, WANG Heng, WU Jianing, ZHAO Yinhuan, WANG Rui, ZHANG Yan, JI Xiaokun. Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 27-31.

References

[1] Mok TS,Wu YL,Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009,361(10):947-957.
[2] Govindan R. Proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer[J]. J Thorac Oncol,2010,5(Sup 6) :433-496.
[3] Lynch TJ,Bell DW,Sordella R,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med 2004,350( 21) :2129-2139.
[4] 刘标,周晓军. 非小细胞肺癌个体化治疗的靶向分子检测[J]. 临床与实验病理学杂志,2012,28(8):831-837.
[5] Nagai Y,Miyazawa H,Hu Q,et al.Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system,the peptide nucleic acid-locked nucleic acid PCR clamp[J].Cancer Res,2005,65(16) :7276-7282.
[6] Lee JS,Park K,Kim SW,et al. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung[R]. San Francisco:13th World Conference on Lung Cance,2009:4.
[7] Tokumo M,Toyooka S,Kiura K,et al. The relationship between epidermal growth factor receptor mutations and clinico-pathologic features in non-small cell lung cancers[J]. Clin Cancer Res,2005,11(3):1167-1173.
[8] Ohba T,Toyokawa G,Kometani T,et al. The mutations of the EGFR and K-RAS genes in resected stage I lung adeno-carcinoma and their clinical significance[J]. Surg Today 2014 44(3):478-486.
[9] Baykara O,Tansarikaya M,Demirkaya A,et al. Association of epidermal growth factor receptor and K-RAS mutations with smoking history in non-small cell lung cancer patients[J]. Exp Ther Med,2013,5(2):495-498.
[10] de Mello RA,Marques DS,Medeiros R,et al. Epidermal growth factor receptor and K-RAS in non-small cell lung cancer-molecular pathways involved and targeted therapies[J]. World J Clin Oncol,2011,2(11):367-376.
[11] 孟加榕,郭以河,张闽峰,等. 肺癌胸水细胞块与组织学EGFR基因扩增检测对比研究[J]. 现代肿瘤医学,2012 20(9):1830-1833.
[12] 王征,武晓楠,穆新林,等. 非小细胞肺癌胸水中癌细胞EGFR基因TK区突变研究[J]. 心肺血管杂志,2009,28(2): 112-116.
[13] 王海彦,庄一平,张晋,等. CT引导下经皮细针穿刺活检检测中晚期肺癌表皮生长因子受体基因突变[J]. 中国介入影像与治疗学,2013,10(1):33-36.

Detection of EGFR gene mutation in non-small cell lung cancer and its clinical significance

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[2]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[3]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.
[4]	YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.
[5]	ZHU Jiawei, HU Xiao, WANG Xijun, WANG Yaru, FENG Lin, XIAO Ting. Clinical significance of Skp1 protein expression in non-small cell lung cancer tissues and peripheral blood [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 89-95.
[6]	ZHANG Jing, TENG Yu, ZHAO Xiaoting, JIANG Mei, YUE Wentao. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(4): 245-250.
[7]	SONG Jie, LI Ping, YU Xuexin, FENG Lin, GAO Yanning, XIAO Ting. Expression of Syntenin in non-small cell lung cancer tissues and its relationship with overall survival of patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 102-105.
[8]	ZHAI Xiaoran, JIANG Mei, ZHAO Xiaoting, GU Meng, YUE Wentao. Clinical significance of PFTK1 expression in human non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(3): 231-235.
[9]	LING Bing，FENG Lin，CHENG Shu-jun. Effect of DENND2Don the cisplatinum cytotoxicity in H1299 cells by regulating PARP1 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(2): 87-90.
[10]	WANG Feng-yun, ZHANG Yan-qiao*, LUO Ming, WU Yun, LI Peng, LI Zhi-wei, SUN Wei. The expressions of p-Stat3 , VEGF-C and MMP-2 in non-small cell lung cancer and their relationship with lymph node metastasis [J]. , 2011, 23(2): 107-110.
[11]	QIU Rong1, SIMA Jun2, SHEN Xiang-di1, ZHOU Ren3. Effect of Hypoxia on Inducing Apoptosis in Non-small Cell Lung Cancer A549 and Expression of Survivin Gene [J]. , 2009, 21(1): 24-026.